Stock & Company Details
Kiniksa Pharmaceuticals Ltd $KNSA
Price:
N/A
N/A
48M
$6.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
80.88
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
KNSA technical indicators
Latest Kiniksa Pharmaceuticals Ltd (KNSA) indicator readings as of 2026-08-18.
KNSA's 14-day RSI is 66.4, in neutral territory. At $79.49 it is trading 58.1% above its 200-day moving average of $50.27, and above its 50-day average of $65.20. Price sits in the middle of its Bollinger Bands ($62.48 to $86.58). ADX reads 40.1, indicating a trending market.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
Finance Bot
Ask your questions
Start by typing a question below.
